NICE Backs Belantamab Mafodotin for Relapsed Myeloma

NICE has recommended belantamab mafodotin for relapsed multiple myeloma, with trial data showing remissions of more than 3 years.
Medscape News UK

Source link : https://www.medscape.com/viewarticle/nice-backs-belantamab-mafodotin-relapsed-myeloma-2026a1000bx0?src=rss

Author :

Publish date : 2026-04-16 15:38:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

NICE Backs Belantamab Mafodotin for Relapsed Myeloma

One in 10 Pharmacies Cloned by Fake Jab Sellers

AI Chat Offered Small Mental Health Boost to College Students in Distress

Related Posts

Trump Taps Former Deputy Surgeon General to Lead CDC

1.8 Billion MASLD Cases; Improving HCC Surveillance; Ultrasound for Crohn’s Disease

Physical Health Key to Seniors’ Mental Health

High Response Rates in Platinum-Resistant Ovarian Cancer With Immunotherapy Agents

RFK Jr. Says He’s Overhauling ‘Lackadaisical’ USPSTF

Phentolamine Eye Drops Ease Presbyopia in Second Randomized Trial

Trump Taps Former Deputy Surgeon General to Lead CDC

1.8 Billion MASLD Cases; Improving HCC Surveillance; Ultrasound for Crohn’s Disease

Physical Health Key to Seniors’ Mental Health

High Response Rates in Platinum-Resistant Ovarian Cancer With Immunotherapy Agents

RFK Jr. Says He’s Overhauling ‘Lackadaisical’ USPSTF

Phentolamine Eye Drops Ease Presbyopia in Second Randomized Trial

Death Rate Among ICE Detainees Surging in 2026

My Libyan Nationality Shouldn’t Make Me a ‘High Risk’ Doctor

Categories

Archives